Liftstream is an executive search recruitment company in the life sciences sector
Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Amsterdam Biotech, Ataluren, Charity, clinical, DART Therapeutics, DMD, Drisapersen, Duchenne Muscular Dystrophy, Eteplirsen, FDA, Gene Williams, Glynn Edwards, GSK, GSK/Prosensa, HT-100, IPO, Market Access, NASDAQ, Netherlands, Orphan drugs, Oxford Biotech, phase II studies, Priority Review, Prosensa, PTC Therapeutics, Rare Disease, regulatory affairs, research and development, Sarepta Therapeutics, Save our Sons, SMT C1100, Summit plc, UK, USA, Utrophin, utrophin modulation
2 Comments
Funding successes allow Promethera to look to clinical data in 2013
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases
Tagged Allogenic Liver Cells, Boehringer Ingelheim, clinical, Crigler-Najjar, Eric Halioua, Etienne Sokal, funding, GMP, HepStem, Liftstream, Liftstream Rare Disease Day, Liver Fibrosis, Phenylketonuria, Promethera Bioscience, rare disease day, RDD13, regenerative medicine, Shire, Stem Cells
1 Comment
Pharma’s emerging markets push creates talent gap
Liftstream looks at how the emerging markets is placing demands on talent and creating gaps in expertise within key functions like regulatory affairs.
Posted in General, Pharmaceutical business
Tagged Biogen IDEC, biotechnology, Brazil, BRIC, celgene, china, clinical, commercial, development, EMA, emerging markets, experience, FDA, G7, Gilead, global, India, N11, Orphan drugs, pharmaceuticals, regulatory affairs, Russia, Saudi Arabia, Shire, Singapore, skills, talent
Leave a comment